|
US4216201A
(en)
*
|
1978-05-22 |
1980-08-05 |
Germaine Monteil Cosmetiques Corp. |
Cosmetic emulsion compositions having skin moisturizing properties
|
|
DE3241113A1
(de)
*
|
1982-11-06 |
1984-05-10 |
Bayer Ag, 5090 Leverkusen |
Vakzinen mit zuschlagstoffen
|
|
US4828991A
(en)
|
1984-01-31 |
1989-05-09 |
Akzo N.V. |
Tumor specific monoclonal antibodies
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US5149650A
(en)
*
|
1986-01-14 |
1992-09-22 |
University Of North Carolina At Chapel Hill |
Vaccines for human respiratory virus
|
|
US5135855A
(en)
|
1986-09-03 |
1992-08-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Rapid, versatile and simple system for expressing genes in eukaryotic cells
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
DE10399032I1
(de)
|
1987-08-28 |
2004-01-29 |
Health Research Inc |
Rekombinante Viren.
|
|
DE3841091A1
(de)
|
1988-12-07 |
1990-06-13 |
Behringwerke Ag |
Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
|
|
EP0378881B1
(en)
|
1989-01-17 |
1993-06-09 |
ENIRICERCHE S.p.A. |
Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
JPH0832638B2
(ja)
|
1989-05-25 |
1996-03-29 |
カイロン コーポレイション |
サブミクロン油滴乳剤を含んで成るアジュバント製剤
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
IT1237764B
(it)
|
1989-11-10 |
1993-06-17 |
Eniricerche Spa |
Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
|
|
FR2658432B1
(fr)
|
1990-02-22 |
1994-07-01 |
Medgenix Group Sa |
Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
|
|
WO1992001070A1
(en)
|
1990-07-09 |
1992-01-23 |
The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce |
High efficiency packaging of mutant adeno-associated virus using amber suppressions
|
|
DE69113564T2
(de)
|
1990-08-13 |
1996-05-30 |
American Cyanamid Co |
Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
|
|
MY109299A
(en)
|
1990-08-15 |
1996-12-31 |
Virogenetics Corp |
Recombinant pox virus encoding flaviviral structural proteins
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
IL101715A
(en)
|
1991-05-02 |
2005-06-19 |
Amgen Inc |
Recombinant dna-derived cholera toxin subunit analogs
|
|
US5378461A
(en)
*
|
1991-07-12 |
1995-01-03 |
Neigut; Stanley J. |
Composition for the topical treatment of skin damage
|
|
AU663725B2
(en)
|
1991-08-20 |
1995-10-19 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Adenovirus mediated transfer of genes to the gastrointestinal tract
|
|
US5229130A
(en)
|
1991-12-20 |
1993-07-20 |
Cygnus Therapeutics Systems |
Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
|
|
IT1253009B
(it)
|
1991-12-31 |
1995-07-10 |
Sclavo Ricerca S R L |
Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
|
|
IT1262896B
(it)
|
1992-03-06 |
1996-07-22 |
|
Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
|
|
US5591601A
(en)
|
1993-05-14 |
1997-01-07 |
Ohio University Edison Animal Biotechnology Institute |
DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
|
|
US5614413A
(en)
|
1993-07-01 |
1997-03-25 |
The Uab Research Foundation |
Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
|
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
|
CN1057915C
(zh)
*
|
1994-09-19 |
2000-11-01 |
中国医学科学院医药生物技术研究所 |
免疫佐剂
|
|
US5676950A
(en)
|
1994-10-28 |
1997-10-14 |
University Of Florida |
Enterically administered recombinant poxvirus vaccines
|
|
IL117483A
(en)
|
1995-03-17 |
2008-03-20 |
Bernard Brodeur |
MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
|
|
EP0750907B1
(en)
*
|
1995-06-30 |
2002-03-20 |
American Cyanamid Company |
Stable macrolide and macrolide vaccine compositions
|
|
GB9622660D0
(en)
|
1996-10-31 |
1997-01-08 |
Biocine Spa |
Immunogenic detoxified mutant toxin
|
|
US6761914B2
(en)
|
1997-05-27 |
2004-07-13 |
Sembiosys Genetics Inc. |
Immunogenic formulations comprising oil bodies
|
|
GB9713156D0
(en)
|
1997-06-20 |
1997-08-27 |
Microbiological Res Authority |
Vaccines
|
|
EP1029052B1
(en)
|
1997-11-06 |
2010-08-04 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisserial antigens
|
|
ES2278420T3
(es)
|
1997-11-21 |
2007-08-01 |
Serono Genetics Institute S.A. |
Secuencia genomica y polipeptidos de chlamydia pneumoniae, fragmentos de los mismos y uso de los mismos, en particular para diagnostico, prevencion y tratamiento de infeccion.
|
|
CN1280619A
(zh)
|
1997-11-28 |
2001-01-17 |
根瑟特公司 |
沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
|
|
JP4150501B2
(ja)
*
|
1997-12-24 |
2008-09-17 |
シャクリー コーポレイション |
紫外光の傷害作用からの高効率皮膚保護を備える組成物
|
|
AU1979599A
(en)
|
1998-01-14 |
1999-08-02 |
Chiron S.P.A. |
(neisseria meningitidis) antigens
|
|
CN100379757C
(zh)
|
1998-05-01 |
2008-04-09 |
希龙公司 |
脑膜炎奈瑟球菌抗原和组合物
|
|
JP2004511201A
(ja)
|
1998-10-09 |
2004-04-15 |
カイロン コーポレイション |
ナイセリアゲノム配列およびそれらの使用方法
|
|
AU1722300A
(en)
|
1998-11-12 |
2000-05-29 |
Regents Of The University Of California, The |
Chlamydia pneumoniae genome sequence
|
|
GB9828000D0
(en)
|
1998-12-18 |
1999-02-10 |
Chiron Spa |
Antigens
|
|
US6329201B1
(en)
|
1998-12-31 |
2001-12-11 |
Chiron Corporation |
Compositions and methods for packaging of alphavirus vectors
|
|
KR100642044B1
(ko)
|
1999-03-19 |
2006-11-10 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
|
EP1165796A2
(en)
|
1999-04-09 |
2002-01-02 |
Techlab, Inc. |
Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
|
|
DE19935763B4
(de)
*
|
1999-07-27 |
2006-03-02 |
Jenning, Volkhard, Dr. |
Zusammensetzung eines Redoxsystems zur Stabilisierung von Retinoiden in Präparaten zur äußerlichen Anwendung
|
|
GB9923060D0
(en)
|
1999-09-29 |
1999-12-01 |
Chiron Spa |
Vaccine
|
|
CA2871789C
(en)
|
2000-01-17 |
2017-04-04 |
Novartis Vaccines And Diagnostics S.R.L. |
Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
|
|
US6767699B2
(en)
|
2000-05-31 |
2004-07-27 |
Chiron Corporation |
Method for the quantitation of alphavirus replicon particles
|
|
AU2001267218C1
(en)
|
2000-06-16 |
2006-07-27 |
Sembiosys Genetics Inc. |
The use of plant oil-bodies in vaccine delivery systems
|
|
ATE440861T1
(de)
|
2000-07-03 |
2009-09-15 |
Novartis Vaccines & Diagnostic |
Immunisierung gegen chlamydia pneumoniae
|
|
KR20020024994A
(ko)
*
|
2000-09-27 |
2002-04-03 |
원인호 |
영양비누물질의 조성과 금은 비누의 제조
|
|
EP1228769A1
(de)
|
2001-02-02 |
2002-08-07 |
Jörg-Peter Prof. Schür |
Symbiontisches Regenerativum
|
|
US6548069B2
(en)
*
|
2001-02-03 |
2003-04-15 |
Hmv Associates, Inc. |
Multivalent Mycoplasma bacterin
|
|
FR2823119B1
(fr)
*
|
2001-04-05 |
2004-02-20 |
Seppic Sa |
Adjuvant d'immunite contenant un cation metallique complexe et vaccin le contenant
|
|
ATE554779T1
(de)
*
|
2001-06-18 |
2012-05-15 |
Neptune Technologies & Bioressources Inc |
Krill zur prävention und/oder behandlung von herz-kreislauf-erkrankungen
|
|
GB0216371D0
(en)
|
2002-07-13 |
2002-08-21 |
Rowett Res Inst The |
Compounds
|
|
JP4456334B2
(ja)
*
|
2003-02-14 |
2010-04-28 |
高砂香料工業株式会社 |
メラニン生成抑制剤及びそれを含有する皮膚外用剤
|
|
CN1960700A
(zh)
|
2004-03-30 |
2007-05-09 |
荷兰联合利华有限公司 |
含维生素和类黄酮的亮肤组合物
|
|
WO2005121378A2
(en)
*
|
2004-06-03 |
2005-12-22 |
Saint Louis University |
Methods and compositions for vaccination
|
|
JP2006028148A
(ja)
*
|
2004-07-14 |
2006-02-02 |
Omori Kitaro |
外用組成物
|
|
US7544816B2
(en)
|
2004-08-19 |
2009-06-09 |
The Hong Kong Polytechnic University |
(−)-Epigallocatechin gallate derivatives for inhibiting proteasome
|
|
JP2006206539A
(ja)
*
|
2005-01-31 |
2006-08-10 |
Biseibutsu Kagaku Kenkyusho:Kk |
アジュバント及びこれを用いたワクチン
|
|
US20060217443A1
(en)
*
|
2005-03-28 |
2006-09-28 |
Kimberly-Clark Worldwide, Inc. |
Method for preventing and/or treating vaginal and vulval infections
|
|
US20070082073A1
(en)
|
2005-05-18 |
2007-04-12 |
University Of South Florida |
Catechin Adjuvants
|
|
JP2009516584A
(ja)
*
|
2005-11-23 |
2009-04-23 |
ネステク ソシエテ アノニム |
新しい製品の稠度を生じるための水中油型エマルション
|
|
EP2046954A2
(en)
*
|
2006-07-31 |
2009-04-15 |
Curevac GmbH |
NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
|
|
DE102006035618A1
(de)
*
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
|
AU2008210290B2
(en)
|
2007-02-01 |
2013-10-31 |
National Research Council Of Canada |
Formulations of lipophilic bioactive molecules
|
|
JP2009165450A
(ja)
|
2008-01-11 |
2009-07-30 |
Otsuka Yakuhin Kogyo Kk |
赤飯用改良剤および、その改良剤を用いた赤飯の製造方法
|
|
EP2278997B1
(en)
*
|
2008-04-21 |
2016-08-10 |
Nanobio Corporation |
Nanoemulsion influenza vaccine
|
|
BRPI1005670A8
(pt)
|
2009-01-05 |
2017-12-26 |
Epitogenesis Inc |
composições adjuvantes e processos de uso.
|
|
EP2305742B1
(en)
|
2009-10-01 |
2017-02-22 |
Symrise AG |
Spherical core-shell-particle
|
|
JP2011105652A
(ja)
|
2009-11-18 |
2011-06-02 |
Oriza Yuka Kk |
美肌用組成物
|
|
BR112013032410A2
(pt)
*
|
2011-06-24 |
2017-01-17 |
Epitogenesis Inc |
composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
|